IL-2 RECEPTOR EXPRESSION AND KI-67 FLOW CYTOMETRIC ANALYSIS IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA

被引:0
|
作者
AYDIN, A
ELNAGGAR, AK
ROBERTSON, LE
KEATING, MJ
HUH, YO
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,DIV PATHOL,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77030
[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030
关键词
CHRONIC LYMPHOCYTIC LEUKEMIA; IL-2; RECEPTOR; PROLIFERATION INDEX; KI-67; RNA INDEX;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is typically an indolent lympho-proliferative disorder. Its clinical course is notable for marked heterogeneity, but in a subset of patients, the disease pursues a relatively rapid clinical course. To identify patients that may have aggressive disease, the growth fraction as determined by Ki-67 proliferation marker, DNA and RNA content, and IL-2 receptor expression were determined in 46 patients with CLL by flow cytometry. Our results indicate a significant statistical correlation between Ki-67 positivity and IL-2 expression in B-CLL cells. No correlation between the proliferative activity or RNA content and IL-2 expression was found. Our data indicate that measurement of both IL-2 receptor and Ki-67 expression in B-CLL can identify a subset of patients with a high risk of rapid clinical progression.
引用
收藏
页码:1433 / 1436
页数:4
相关论文
共 50 条
  • [31] PHENYLACETATE IS CYTOTOXIC TO B-CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL) CELLS
    CALL, TG
    STENSON, MJ
    WITZIG, TE
    BLOOD, 1993, 82 (10) : A561 - A561
  • [32] MYELOMONOCYTIC ASSOCIATED ANTIGENS IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA - ANALYSIS OF CLINICAL-SIGNIFICANCE
    MOLICA, S
    DATTILO, A
    ALBERTI, A
    LEUKEMIA & LYMPHOMA, 1991, 5 (2-3) : 139 - 144
  • [33] APOPTOSIS AS AN INDICATOR FOR STEROID SENSITIVITY OF LYMPHOCYTES IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    VISHLITZKY, V
    NESSABRAMOF, R
    ZEMER, R
    ELLIS, M
    LISHNER, M
    MANOR, Y
    YUKLEA, MS
    KLEIN, A
    ONCOLOGY REPORTS, 1995, 2 (03) : 461 - 463
  • [34] FUNCTIONAL DIFFERENCES OF T-CELLS IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    ANTICA, M
    KUSIC, B
    SPAVENTI, R
    JAKSIC, B
    VITALE, B
    LEUKEMIA & LYMPHOMA, 1993, 9 (1-2) : 133 - 140
  • [35] METHYLTHIOADENOSINE PHOSPHORYLASE AND PURINE NUCLEOSIDE PHOSPHORYLASE IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    VERTONGEN, F
    MANDELBAUM, I
    THYMUS, 1984, 6 (06) : 359 - 364
  • [36] hTERT expression and prognosis in B-chronic lymphocytic leukemia
    Tchirkov, A
    Chaleteix, C
    Magnac, C
    Vasconcelos, Y
    Davi, F
    Michel, A
    Kwìatkowski, F
    Tournilhac, O
    Dighiero, G
    Travade, P
    ANNALS OF ONCOLOGY, 2004, 15 (10) : 1476 - 1480
  • [37] MONOCLONAL AND OLIGOCLONAL IMMUNOGLOBULINS IN THE SERUM OF PATIENTS WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    PANGALIS, GA
    MOUTSOPOULOS, HM
    PAPADOPOULOS, NM
    COSTELLO, R
    KOKKINOU, S
    FESSAS, P
    ACTA HAEMATOLOGICA, 1988, 80 (01) : 23 - 27
  • [38] CD11C POSITIVE B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    TASSIES, D
    MONTSERRAT, E
    VILLAMOR, N
    ROZMAN, C
    BLOOD, 1991, 78 (07) : 1893 - 1893
  • [39] EFFECTS OF PHENYLACETATE ON CELLS FROM PATIENTS WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA
    CALL, TG
    STENSON, MJ
    WITZIG, TE
    LEUKEMIA & LYMPHOMA, 1994, 14 (1-2) : 145 - 149
  • [40] THE USE OF CYCLOSPORINE-A IN THE TREATMENT OF B-CHRONIC LYMPHOCYTIC-LEUKEMIA - REPLY
    BERGUI, L
    GREGORETTI, MG
    CALIGARISCAPPIO, F
    LEUKEMIA, 1995, 9 (02) : 358 - 359